Filters








136 Hits in 9.1 sec

Privacy in Pharmacogenetics: An End-to-End Case Study of Personalized Warfarin Dosing Privacy in Pharmacogenetics: An End-to-End Case Study of Personalized Warfarin Dosing

Matthew Fredrikson, Eric Lantz, Somesh Jha, Simon Lin, David Page, Thomas Ristenpart, Matthew Fredrikson, Eric Lantz, Somesh Jha, Simon Lin, David Page, Thomas Ristenpart
unpublished
Performing an in-depth case study on privacy in personalized warfarin dosing, we show that suggested models carry privacy risks, in particular because attackers can perform what we call model inversion  ...  We initiate the study of privacy in pharmacogenetics, wherein machine learning models are used to guide medical treatments based on a patient's genotype and background.  ...  To do so, we perform a case study of warfarin dosing, a popular target for pharmacogenetic modeling.  ... 
fatcat:uz74oibm7fcfjkfdeucfi5g3uu

Privacy in Pharmacogenetics: An End-to-End Case Study of Personalized Warfarin Dosing

Matthew Fredrikson, Eric Lantz, Somesh Jha, David Page, Thomas Ristenpart, Simon Lin
unpublished
) 13 This Talk We introduce an attack called model inversion New Attack End-to-End Study Differential privacy prevents the attack Risk of adverse outcomes is too high with DP Extract  ...  trained from the original data 19 This Talk We introduce an attack called model inversion New Attack End-to-End Study Differential privacy prevents the attack Risk of adverse outcomes  ... 
fatcat:gojsvwtllrhnrhxispjudfwhvu

Privacy in Pharmacogenetics: An End-to-End Case Study of Personalized Warfarin Dosing

Matthew Fredrikson, Eric Lantz, Somesh Jha, Simon Lin, David Page, Thomas Ristenpart
2014
Performing an in-depth case study on privacy in personalized warfarin dosing, we show that suggested models carry privacy risks, in particular because attackers can perform what we call model inversion  ...  We initiate the study of privacy in pharmacogenetics, wherein machine learning models are used to guide medical treatments based on a patient's genotype and background.  ...  To do so, we perform a case study of warfarin dosing, a popular target for pharmacogenetic modeling.  ... 
pmid:27077138 pmcid:PMC4827719 fatcat:2qcz36jhvbcqbjtikkgmfyppum

Pharmacogenetics: Matching the Right Foundation at Personalized Medicine in the Right Genomic Era [chapter]

Roxana-Georgiana Tauser
2012 Clinical Applications of Pharmacogenetics  
set of polymorphisms, in cases where there are large cohorts to evaluate, clinical end points are simple to define without variability, and the genetic factors associated with the end points are highly  ...  (Stingl & Brockmöller, 2011) www.intechopen.com Clinical Applications of Pharmacogenetics 20 The case-control Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation (SHAPE) showed that  ...  Pharmacogenetics: Matching the Right Foundation at Personalized Medicine in the Right Genomic Era, Clinical Applications of Pharmacogenetics, Dr.  ... 
doi:10.5772/25824 fatcat:hiwurkotunf2na2jslddxiyicu

PS3-2: Informatics Challenges to Implement Pharmacogenetics to Clinical Practice

Z. Zhou, M. He, M. Brilliant, A. Brautbar, A. Miller, B. Weichelt, S. Lin
2013 Clinical Medicine & Research  
Conclusions: These results confirm those of previous studies and demonstrate the power of the GERA cohort for combining information from electronic medical records with extensive genotype data.  ...  We identified a total of 2,147 AMD cases (46 Asian, 125 Latino, 11 African American, and 1,965 non-Hispanic whites) and 37,521 controls (2,013 Asian, 3,201 Latino, 1,168 African American, and 31,139 non-Hispanic  ...  Results: We enrolled 265 cases and 305 controls with an average of 3.4 and 3.7 years of warfarin use at the index date, respectively.  ... 
doi:10.3121/cmr.2013.1176.ps3-2 fatcat:7b2ejmx2bjbgfosmqp2pnh3rpm

Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation

Frank S Ong, Joshua L Deignan, Jane Z Kuo, Kenneth E Bernstein, Jerome I Rotter, Wayne W Grody, Kingshuk Das
2012 Pharmacogenomics (London)  
The greatest obstacle to clinical implementation of cardiovascular pharmacogenetics may be the lack of both reproducibility and agreement about the validity and utility of the findings.  ...  In this review, we present the scientific evidence in the literature for diagnostic variants for the US FDA-labeled cardiovascular therapies, namely CYP2C19 and clopidogrel, CYP2C9/ VKORC1 and warfarin  ...  to warfarin and reduction in dose requirement.  ... 
doi:10.2217/pgs.12.2 pmid:22380001 pmcid:PMC3306231 fatcat:uwgz5wrmlfhvflqbwivz4tgixu

A Proposal for an Individualized Pharmacogenetic-Guided Warfarin Dosage Regimen for Puerto Rican Patients Commencing Anticoagulation Therapy

Luis Angel Bermudez Bosch
2013 Journal of Pharmacogenomics & Pharmacoproteomics  
A customized pharmacogenetic-based warfarin maintenance dose algorithm (R2=0.7659) was developed in a derivation cohort of 131 patients.  ...  Warfarin is the current standard of care in oral anticoagulation therapy.  ...  Acknowledgments Funding Details This investigation was supported in part by a grant from the National Heart, Lung and Blood Institute (SC2HL110393); the Research Center in Minority Institutions (RCMI  ... 
doi:10.4172/2153-0645.t-001 pmid:25285240 pmcid:PMC4181534 fatcat:s5vpbkfbefctvn74cz2iljgbsa

Introducing Pharmacogenetics and Personalized Medicine via a Weblog

Kaitlin Bova, Sara Bova, Kevin Hill, Mark Dixon, Diana Ivankovich, David F. Kisor
2014 INNOVATIONS in Pharmacy  
Notably, following the course, students had an increased knowledge base relative to "genetic privacy", drug dosing based on metabolizer phenotype, and the breadth of PM, among other specific points.  ...  The blog format is easily transferable and can be adopted by colleges/schools to introduce PGt and PM. Type: Case Study  ...  In an effort to develop an introductory course in PGt and PM, a study was undertaken to evaluate the use of a blog course to increase the knowledge base of freshmen students.  ... 
doi:10.24926/iip.v5i2.333 fatcat:ji6fgurpovgyxmduin53zses4q

Secure Evaluation Protocol for Personalized Medicine

Mentari Djatmiko, Arik Friedman, Roksana Boreli, Felix Lawrence, Brian Thorne, Stephen Hardy
2014 Proceedings of the 13th Workshop on Privacy in the Electronic Society - WPES '14  
In this paper, we propose a secure evaluation algorithm to compute genomic tests that are based on a linear combination of genome data values (we use the Warfarin dosing algorithm as a representative example  ...  We implement a prototype system that includes the Paillier encryption part of our protocol in an Android app and back-end server architecture.  ...  We use the Warfarin Pharmacogenetic dosing [13] algorithm as an example of such tests.  ... 
doi:10.1145/2665943.2665967 dblp:conf/wpes/DjatmikoFBLTH14 fatcat:pfcjfeol6bearbnovpduf7wvse

Assessment of patient perceptions of genomic testing to inform pharmacogenomic implementation

Yee Ming Lee, Ryan P. McKillip, Brittany A. Borden, Catherine E. Klammer, Mark J. Ratain, Peter H. O'Donnell
2017 Pharmacogenetics & Genomics  
We sought to understand attitudes and perceptions of patients in an institutional implementation project and hypothesized that views would differ based on experience with pharmacogenomicguided care.  ...  Case scenarios and tested educational materials elicited strong desires on the part of patients for physicians to engage participants when considering pharmacogenomic-based prescribing, and to utilize  ...  The first vignette illustrated how pharmacogenomic information predicted a lower warfarin dose due to CYP2C9 and VKORC1 gene polymorphisms.  ... 
doi:10.1097/fpc.0000000000000275 pmid:28267054 pmcid:PMC5478379 fatcat:iqvr366atbh3lfg3yd6fokqwru

Challenges Faced in the Integration of Pharmacogenetics/Genomics into Drug Development

Maria Luisa Brandi, Abadie Eric, Daly Ann, Dere Willard
2012 Journal of Pharmacogenomics & Pharmacoproteomics  
and an increasing number of requests for inclusion of pharmacogenetic discoveries in drug labels.  ...  The areas for discussion amongst the participants included design of pharmacogenetic studies, regulatory requirements in the European Union, pharmacokinetic and pharmacodynamic aspects with a proposal  ...  Acknowledgements This work was supported by an unrestricted grant of the Group for the Respect of Ethics and Excellence in Science (GREES).  ... 
doi:10.4172/2153-0645.1000108 fatcat:3sm7pusq6jhyhevrkujhoi5c4q

The impact of pharmacogenetics and pharmacogenomics

Klaus Lindpaintner
2003 Journal of Commercial Biotechnology  
Pharmacogenetics is widely proclaimed as about to revolutionise the face of medicine.  ...  In a more realistic assessment, the implementation of molecular genetics and biology will continue to provide, as it has done already, better ways to diagnose and treat illnesses, but it will do so at  ...  It will be of key importance for all concerned to engage in an intensive dialogue at the end of which -it is hoped -will emerge a joint understanding that stratification according to DNA-based markers  ... 
doi:10.5912/jcb56 fatcat:mc3lochpqraetp2ahtsbarcxau

FARMAPRICE: A Pharmacogenetic Clinical Decision Support System for Precise and Cost-Effective Therapy

Rossana Roncato, Lisa Dal Cin, Silvia Mezzalira, Francesco Comello, Elena De Mattia, Alessia Bignucolo, Lorenzo Giollo, Simone D'Errico, Antonio Gulotta, Luca Emili, Vincenzo Carbone, Michela Guardascione (+3 others)
2019 Genes  
Pharmacogenetic (PGx) guidelines for the precise dosing and selection of drugs remain poorly implemented in current clinical practice.  ...  The present study aimed to describe the first Italian endeavor to develop a PGx CDSS, called FARMAPRICE.  ...  The funders played no role in the design of the study; in the collection, analyses, or interpretation of data; in writing the manuscript, or in the decision to publish the results.  ... 
doi:10.3390/genes10040276 pmid:30987397 pmcid:PMC6523070 fatcat:eqqlnpzsuvdk3oy6k3sjfweoti

Pharmacogenetic Testing for Uridine Diphosphate Glucuronosyltransferase 1A1 Polymorphisms: Are We There Yet?

Minoli A Perera, Federico Innocenti, Mark J Ratain
2008 Pharmacotherapy  
With the end of the human genome project and the wealth of information readily Isoform Pharmacogenetics of UGTIAI1 =aiscpatieeih-leaaeialinies available online,’ the promise of personalized Protease Inhibitors  ...  Recent changes to the labels of three prescription drugs—irinotecan, 6-mercaptopurine, and warfarin—include recommendations for pharmacogenetic testing in patients.  ... 
doi:10.1592/phco.28.6.755 pmid:18503403 fatcat:ngwp6ma34zdj7iz43mo36xgzn4

Membership Privacy in MicroRNA-based Studies

Michael Backes, Pascal Berrang, Mathias Humbert, Praveen Manoharan
2016 Proceedings of the 2016 ACM SIGSAC Conference on Computer and Communications Security - CCS'16  
study, it is possible to detect if this individual participated in the study.  ...  In this paper, we show that the membership inference attack also threatens the privacy of individuals contributing their microRNA expressions to scientific studies.  ...  In the pharmacogenetics context, Fredrikson et al. show that differential privacy mechanisms can induce bad warfarin dosing, thus expose patients to an increased risk of stroke, bleeding events, and mortality  ... 
doi:10.1145/2976749.2978355 dblp:conf/ccs/0001BHM16 fatcat:kumx7xqsljbzrcgsgj2vz5bgfu
« Previous Showing results 1 — 15 out of 136 results